Literature DB >> 22890802

3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy.

Mahila E Ferrari1, Marta Cremonesi, Amalia Di Dia, Francesca Botta, Concetta De Cicco, Anna Sarnelli, Piernicola Pedicini, Michele Calabrese, Roberto Orecchia, Guido Pedroli, Giovanni Paganelli.   

Abstract

PURPOSE: Intraoperative Avidination for Radionuclide Therapy (IART) is a novel targeted radionuclide therapy recently used in patients with early breast cancer. It is a radionuclide approach with (90)Y-biotin combined with external beam radiotherapy (EBRT) to release a boost of radiation in the tumour bed. Two previous clinical trials using dosimetry based on the calculation of mean absorbed dose values with the hypothesis of uniform activity distribution (MIRD 16 method) assessed the feasibility and safety of IART. In the present retrospective study, a voxel dosimetry analysis was performed to investigate heterogeneity in distribution of the absorbed dose. The aim of this work was to compare dosimetric and radiobiological evaluations derived from average absorbed dose vs. voxel absorbed dose approaches.
METHODS: We evaluated 14 patients who were injected with avidin into the tumour bed after conservative surgery and 1 day later received an intravenous injection of 3.7 GBq of (90)Y-biotin (together with 185 MBq (111)In-biotin for imaging). Sequential images were used to estimate the absorbed dose in the target region according to the standard dosimetry method (SDM) and the voxel dosimetry method (VDM). The biologically effective dose (BED) distribution was also evaluated. Dose/volume and BED volume histograms were generated to derive equivalent uniform BED (EUBED) and equivalent uniform dose (EUD) values.
RESULTS: No "cold spots" were highlighted by voxel dosimetry. The median absorbed-dose in the target region was 20 Gy (range 15-27 Gy) by SDM, and the median EUD was 20.4 Gy (range 16.5-29.4 Gy) by the VDM; SDM and VDM estimates differed by about 6 %. The EUD/mean voxel absorbed dose ratio was >0.9 in all patients, indicative of acceptable uniformity in the target. The median BED and EUBED values were 21.8 Gy (range 15.9-29.3 Gy) and 22.8 Gy (range 17.3-31.8 Gy), respectively.
CONCLUSION: VDM highlighted the absence of significant heterogeneity in absorbed dose in the target. The EUD/mean absorbed dose ratio indicated a biological efficacy comparable to that of uniform distribution of absorbed dose. The VDM is recommended for improving accuracy, taking into account actual activity distribution in the target region. The radiobiological model applied allowed us to compare the effects of IART® with those of EBRT and to match the two irradiation modalities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890802     DOI: 10.1007/s00259-012-2197-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

1.  Treatment plan comparison using equivalent uniform biologically effective dose (EUBED).

Authors:  L C Jones; P W Hoban
Journal:  Phys Med Biol       Date:  2000-01       Impact factor: 3.609

2.  Radionuclide and radiation protection data handbook 2nd edition (2002).

Authors:  D Delacroix; J P Guerre; P Leblanc; C Hickman
Journal:  Radiat Prot Dosimetry       Date:  2002       Impact factor: 0.972

3.  A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions.

Authors:  N Lanconelli; M Pacilio; S Lo Meo; F Botta; A Di Dia; A Torres Aroche; M A Coca Pérez; M Cremonesi
Journal:  Phys Med Biol       Date:  2012-01-21       Impact factor: 3.609

4.  MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature.

Authors:  Wesley E Bolch; Keith F Eckerman; George Sgouros; Stephen R Thomas
Journal:  J Nucl Med       Date:  2009-03       Impact factor: 10.057

5.  IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation.

Authors:  Giovanni Paganelli; Mahila Ferrari; Marta Cremonesi; Concetta De Cicco; Viviana Galimberti; Alberto Luini; Paolo Veronesi; Maurizio Fiorenza; Paolo Carminati; Claudio Zanna; Roberto Orecchia; Umberto Veronesi
Journal:  Breast       Date:  2006-12-14       Impact factor: 4.380

6.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Authors:  Michael G Stabin; Richard B Sparks; Eric Crowe
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

7.  131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Peter L Roberson; Scott J Wilderman; Hanan Amro; Denise D Regan; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

8.  A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy.

Authors:  Robert F Hobbs; Todd McNutt; Sébastien Baechler; Bin He; Caroline E Esaias; Eric C Frey; David M Loeb; Richard L Wahl; Ori Shokek; George Sgouros
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

9.  Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer.

Authors:  Giovanni Paganelli; Mahila Ferrari; Laura Ravasi; Marta Cremonesi; Concetta De Cicco; Viviana Galimberti; Gregory Sivolapenko; Alberto Luini; Rita De Santis; Laura Lavinia Travaini; Maurizio Fiorenza; Marco Chinol; Stefano Papi; Claudio Zanna; Paolo Carminati; Umberto Veronesi
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

10.  Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

Authors:  Christiane Wehrmann; Stefan Senftleben; Carolin Zachert; Dirk Müller; Richard P Baum
Journal:  Cancer Biother Radiopharm       Date:  2007-06       Impact factor: 3.099

View more
  7 in total

Review 1.  Improving external beam radiotherapy by combination with internal irradiation.

Authors:  A Dietrich; L Koi; K Zöphel; W Sihver; J Kotzerke; M Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

2.  Defining the role for dosimetry and radiobiology in combination therapies.

Authors:  Manuel Bardiès; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01       Impact factor: 9.236

3.  Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.

Authors:  Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-03       Impact factor: 9.236

Review 4.  Dosimetry for radiopharmaceutical therapy.

Authors:  George Sgouros; Robert F Hobbs
Journal:  Semin Nucl Med       Date:  2014-05       Impact factor: 4.446

5.  Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry.

Authors:  Ti-Hao Wang; Pin-I Huang; Yu-Wen Hu; Ko-Han Lin; Ching-Sheng Liu; Yi-Yang Lin; Chien-An Liu; Hsiou-Shan Tseng; Yu-Ming Liu; Rheun-Chuan Lee
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

6.  Yttrium-90 quantitative phantom study using digital photon counting PET.

Authors:  Joey Labour; Philippe Boissard; David Sarrut; Jean-Noël Badel; Thomas Baudier; Fouzi Khayi; David Kryza; Pascale Veyrat Durebex; Sandrine Parisse-Di Martino; Thomas Mognetti
Journal:  EJNMMI Phys       Date:  2021-07-27

Review 7.  Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective.

Authors:  Marta Cremonesi; Carlo Chiesa; Lidia Strigari; Mahila Ferrari; Francesca Botta; Francesco Guerriero; Concetta De Cicco; Guido Bonomo; Franco Orsi; Lisa Bodei; Amalia Di Dia; Chiara Maria Grana; Roberto Orecchia
Journal:  Front Oncol       Date:  2014-08-19       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.